2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
复制标题
DOI:
10.1016/j.joa.2015.12.001
复制
发表时间:
2016-02
影响因子:
2
通讯作者:
Zhang S
中科院分区:
文献类型:
--
作者:
Wilkoff BL;Fauchier L;Stiles MK;Morillo CA;Al-Khatib SM;Almendral J;Aguinaga L;Berger RD;Cuesta A;Daubert JP;Dubner S;Ellenbogen KA;Estes NA 3rd;Fenelon G;Garcia FC;Gasparini M;Haines DE;Healey JS;Hurtwitz JL;Keegan R;Kolb C;Kuck KH;Marinskis G;Martinelli M;McGuire M;Molina LG;Okumura K;Proclemer A;Russo AM;Singh JP;Swerdlow CD;Teo WS;Uribe W;Viskin S;Wang CC;Zhang S
Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected patients in definable populations. The benefits and risks of ICD therapy are directly impacted by programming and surgical decisions. This flexibility is both a great strength and a weakness, for which there has been no prior official discussion or guidance. It is the consensus of the four continental electrophysiology societies that there are four important clinical issues for which there are sufficient ICD clinical and trial data to provide evidence-based expert guidance. This document systematically describes the. 80%(83–100%, mean: 96%) required consensus achieved for each recommendation by official balloting in regard to the programming of (i) bradycardia mode and rate,(ii) tachycardia detection,(iii) tachycardia therapy, and (iv) the intraprocedural testing of defibrillation efficacy. Representatives nominated by the Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA), Asian Pacific Heart Rhythm Society (APHRS), and the